Dual factor coactivatable fluorescent nanosensor with boosted cytoplasmic biomarker accessibility toward selective tumor imaging

Chen, Yuhua; Xing, Yuxin; Wang, Zhenqiang; Li, Lin; Wang, Hailin; Tang, Shuqi; Cai, Kun; Zhang, Jixi

doi:10.1016/j.bios.2022.115026

Cited by 4 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spatial miRNA expression analysis can also be carried out in vivo, via in-situ hybridization of fluorescently labelled oligonucleotide probes of complementary sequence to target miRNAs. Numerous reports describe application of this approach to tumour imaging, including use of fluorescence boosting to localise miR-21 in mouse tumours [29][30][31][32]. Pawluczyk et al [7 && ] used in-situ hybridization to determine that miR-150 was localised to lymphoid infiltrates during IgAN.…”

Section: Spatial Analysis and Mechanistic Insightsmentioning

confidence: 99%

Identification and detection of microRNA kidney disease biomarkers in liquid biopsies

Smith,

Redman,

Fraser

et al. 2023

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of review MicroRNAs (miRNAs) are emerging rapidly as a novel class of biomarkers of major organ disorders, including kidney diseases. However, current PCR-based detection methods are not amenable to development for high-throughput, cost-effective miRNA biomarker quantification. Recent findings MiRNA biomarkers show significant promise for diagnosis and prognosis of kidney diseases, including diabetic kidney disease, acute kidney injury, IgA nephropathy and delayed graft function following kidney transplantation. A variety of novel methods to detect miRNAs in liquid biopsies including urine, plasma and serum are being developed. As miRNAs are functional transcripts that regulate the expression of many protein coding genes, differences in miRNA profiles in disease also offer clues to underlying disease mechanisms. Summary Recent findings highlight the potential of miRNAs as biomarkers to detect and predict progression of kidney diseases. Developing in parallel, novel methods for miRNA detection will facilitate the integration of these biomarkers into rapid routine clinical testing and existing care pathways. Validated kidney disease biomarkers also hold promise to identify novel therapeutic tools and targets. Video abstract http://links.lww.com/CONH/A43

show abstract

Section: Spatial Analysis and Mechanistic Insightsmentioning

confidence: 99%

Identification and detection of microRNA kidney disease biomarkers in liquid biopsies

Smith,

Redman,

Fraser

et al. 2023

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

show abstract

“…The construction of nucleic acid probes facilitates the exploration of information in complex biological system. , Particularly, nucleic acid probes can integrate signal amplification strategies that can amplify a single nucleic acid over thousands of times to improve sensitivity. Several enzyme-assisted signal amplification strategies such as loop-mediated isothermal amplification and rolling circle amplification were proposed. − However, these methods are facing the problem of enzyme transportation, which limits their application in living cell imaging. , Alternative enzyme-free amplification strategies, such as hybridization chain reaction (HCR), cascade hybridization reaction (CHA), DNAzyme-based amplification, etc., that can spontaneously occur with the trigger of target nucleic acids have been widely applied in intracellular miRNA imaging. − …”

mentioning

confidence: 99%

DNAzyme-Amplified Cascade Catalytic Hairpin Assembly Nanosystem for Sensitive MicroRNA Imaging in Living Cells

Huang

Tong

et al. 2023

Anal. Chem.

View full text Add to dashboard Cite

Sensitive imaging of microRNAs (miRNAs) in living cells is significant for accurate cancer clinical diagnosis and prognosis research studies, but it is challenged by inefficient intracellular delivery, instability of nucleic acid probes, and limited amplification efficiency. Herein, we engineered a DNAzymeamplified cascade catalytic hairpin assembly (CHA)-based nanosystem (DCC) that overcomes these challenges and improves the imaging sensitivity. This enzyme-free amplification nanosystem is based on the sequential activation of DNAzyme amplification and CHA. MnO 2 nanosheets were used as nanocarriers for the delivery of nucleic acid probes, which can resist the degradation by nucleases and supply Mn 2+ for the DNAzyme reaction. After entering into living cells, the MnO 2 nanosheets can be decomposed by intracellular glutathione (GSH) and release the loaded nucleic acid probes. In the presence of target miRNA, the locking strand (L) was hybridized with target miRNA, and the DNAzyme was released, which then cleaved the substrate hairpin (H 1 ). This cleavage reaction resulted in the formation of a trigger sequence (TS) that can activate CHA and recover the fluorescence readout. Meanwhile, the DNAzyme was released from the cleaved H 1 and bound to other H 1 for new rounds of DNAzyme-based amplification. The TS was also released from CHA and involved in the new cycle of CHA. By this DCC nanosystem, low-abundance target miRNA can activate many DNAzyme and generate numerous TS for CHA, resulting in sensitive and selective analysis of miRNAs with a limit of detection of 5.4 pM, which is 18-fold lower than that of the traditional CHA system. This stable, sensitive, and selective nanosystem holds great potential for miRNA analysis, clinical diagnosis, and other related biomedical applications.

show abstract

Flower‐Like Nanosensors for Photoacoustic‐Enhanced Lysosomal Escape and Cytoplasmic Marker‐Activated Fluorescence: Enabling High‐Contrast Identification and Photothermal Ablation of Minimal Residual Disease in Breast Cancer

Li,

Xing,

Chen

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

The clearance of minimal residual disease (MRD) after breast cancer surgery is crucial for inhibiting metastasis and recurrence. However, the most promising biomarker‐activated fluorescence imaging strategies encounter accessibility issues of the delivered sensors to cytoplasmic targets. Herein, a flower‐like composite nanosensor with photoacoustic (PA) effect‐enhanced lysosomal escape and cytoplasmic marker‐activated fluorescence is developed to address this challenge. Specifically, the incorporation of Co2+ into the synthesis of 2D Zn2+‐derived metal–organic frameworks enabled rapid dopamine polymerization and deposition. Subsequently, the composite nanoflower (FHN), characterized by an average size of ≈80 nm and petal thickness of ≈6 nm, is formed through the sealing of micropores and simultaneous cross‐linking of nanosheets. The pronounced reduction in thermal conductivity of FHN, and superposition of interpetal thermal fields under a pulsed laser (PL), lead to enhanced PA effect and membrane permeability. Thereby, nanosensors efficiently escape from lysosomes resulting in synergistic fluorescence activation by dual‐factors (ATP, miRNA‐21) and DNA probes installed on FHN. A subsequently high tumor‐to‐normal tissue signal ratio (TNR) of 17.4 lead to precise guidance of NIR irradiation for efficient MRD eradication and recurrence inhibition. This study provides a new approach for high‐contrast identification and precise ablation of MRD based on the synergistic response of endogenous and exogenous factors.

show abstract

Dual factor coactivatable fluorescent nanosensor with boosted cytoplasmic biomarker accessibility toward selective tumor imaging

Cited by 4 publications

References 48 publications

Identification and detection of microRNA kidney disease biomarkers in liquid biopsies

Identification and detection of microRNA kidney disease biomarkers in liquid biopsies

DNAzyme-Amplified Cascade Catalytic Hairpin Assembly Nanosystem for Sensitive MicroRNA Imaging in Living Cells

Flower‐Like Nanosensors for Photoacoustic‐Enhanced Lysosomal Escape and Cytoplasmic Marker‐Activated Fluorescence: Enabling High‐Contrast Identification and Photothermal Ablation of Minimal Residual Disease in Breast Cancer

Contact Info

Product

Resources

About